Lyme Disease



2019 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease (final publication of guideline anticipated in late 2019)

Call for Public Comment

The Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR) are accepting comments on the draft of the 2019 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. We are looking for feedback from not only physicians and healthcare professionals, but also individuals affected by Lyme disease, such as patients, care givers, patient organization members, advocates, and researchers. The draft and comment form will be available for 45 days.

Submit a Comment
View the draft guidelines and supplementary materials and submit comments on the IDSA website. The deadline to submit comments is August 10.

Guideline Development

The IDSA, AAN, and ACR are jointly developing a systematic review and guideline on treatment of Lyme disease. The author composition is made up of representatives from IDSA, AAN, and ACR with representation from the American Academy of Family Physicians (AAFP), American Academy of Pediatrics - Committee on Infectious Diseases (AAP-COID), American Academy of Pediatrics - Section on Emergency Medicine (AAP-EM), American College of Physicians (ACP), Association of Medical Microbiology and Infectious Diseases - Canada (AMMI-CA), Child Neurology Society (CNS), Pediatric Infectious Diseases Society (PIDS), Entomological Society of America (ESA), and European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Members representing the disciplines of cardiology, microbiology, pathology, and a methodologist with expertise in GRADE are also included. Finally, the panel includes a healthcare consumer representative, three patients with confirmed Lyme disease, and a parent of a pediatric patient with confirmed Lyme disease.

The societies are utilizing the IDSA guideline development process, which includes the widely accepted GRADE methodology and are adhering to the Institute of Medicine (IOM) Standards for Developing Trustworthy Clinical Practice Guidelines. These rigorous standards are meant to assure objective, transparent, and scientifically valid systematic reviews and clinical practice guidelines.

In 2015, the guideline panel held a public comment period requesting input on its project plan that laid the ground work for new Lyme disease guidelines. The panel has published its response to the input received during the public comment period.

© 2019 American College of Rheumatology.  All rights reserved.  Website & Privacy Policies | Sitemap | Help | Contact Us